title: Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study.
abstract: BACKGROUND
  We investigated the effects of the relative increase in testosterone by dutasteride administration in patients with benign prostatic hyperplasia and hypogonadism on urinary symptoms or androgen-responsive general health.
  
  
  METHODS
  Seventy-six patients were enrolled, and were taking 0.5 mg dutasteride daily for 52 weeks. Before and after treatment, all participants underwent blood test, and body mass index, prostate volume (PV), bone mineral density (BMD), post-voiding residual (PVR) volume, and muscle volume were measured. All patients responded to the questionnaires: International prostatic symptom score (IPSS), Overactive Bladder Symptom score (OABSS). Patients were divided into two groups according to the increase rate of total testosterone (TT): group A, ≥20% increase in TT level; group B, <20% increase or decrease.
  
  
  RESULTS
  Baseline TT and free testosterone (FT) levels were significantly lower in group A than group B. Both groups showed marked improvement in PV and PVR. Group A showed significant improvement in IPSS and OABSS with a significant increase of FT level, whereas group B showed no significant change. Dutasteride treatment contributed to a significant increase in BMD in group A.
  
  
  CONCLUSIONS
  Dutasteride treatment significantly improved urinary symptoms and BMD in patients with low baseline serum TT and FT levels.
authors.affiliation: Department of Urology, Ishikawa Prefectural Central Hospital , Kanazawa City , Japan and.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Shigehara
authors.forename: Eitetsu
authors.initials: E
authors.lastname: Koh
authors.forename: Jiro
authors.initials: J
authors.lastname: Sakamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yaegashi
authors.forename: Koji
authors.initials: K
authors.lastname: Izumi
authors.forename: Satoru
authors.initials: S
authors.lastname: Ueno
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Maeda
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Kadono
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Konaka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
authors.forename: Takao
authors.initials: T
authors.lastname: Nakashima
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001378:Azasteroids / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D000068538:Dutasteride; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D001378:Azasteroids; D064804:Urological Agents; D013739:Testosterone; D000068538:Dutasteride